Regulatory News
Wednesday, May 18, 2016
BRIEF-ImmunoGen reports positive early-stage data on ovarian cancer drug
* Reports efficacy and safety data from a 46 patient cohort
of mirvetuximab soravtansine in fr-positive ovarian cancer
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment